Journal of Oncology / 2014 / Article / Tab 3 / Review Article
The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis Table 3 Patient characteristics of included zoledronic acid trials.
Characteristic Immediate group Delayed group Z FAST ZO FAST E-ZO FAST Z FAST ZO FAST E-ZO FAST Age, years Median 60 57 58 60 58 58 Range 35–83 36–87 40–81 41–89 37–81 44–78 Race White 280 — 226 269 — 242 Asian — 89 21 — 93 19 Black 9 — — 14 — — Caucasian — 416 — — 409 — Other 12 27 5 18 31 9 Baseline
score
score > −1 217 370 163 216 367 180
score ≤ −1 to ≥ −2 84 162 89 85 166 90 Postmenopausal status Postmenopausal 281 445 210 284 443 228 Recently postmenopausal — 87 42 — 90 42 Bone mineral density Lumbar spine Mean 1.110 1.08 1.106 1.08 SD 0.1652 0.16 0.1663 0.16 Median 1.088 1.07 — 1.082 1.06 — Range 0.818–1.649 0.79–1.67 0.807–1.692 0.71–1.77 Total hip Mean 0.958 0.96 0.955 0.96 SD 0.1259 0.13 — 0.1322 0.13 — Median 0.954 0.94 0.943 0.94 Range 0.676–1.310 0.62–1.43 0.700–1.475 0.62–1.55